Pomerantz Law Firm has initiated a class action lawsuit against Vistagen Therapeutics, Inc. (NASDAQ: VTGN) following the company's announcement that its PALISADE-3 Phase 3 clinical trial for intranasal fasedienol failed to meet its primary efficacy endpoint in treating social anxiety disorder. The trial failure triggered a significant market reaction, with Vistagen's stock declining 80.25% on December 17, 2025, eroding shareholder value substantially.
The litigation alleges potential violations of securities laws based on the clinical trial outcome. Investors who sustained losses during the relevant period are being urged to take action before the March 16, 2026 deadline to participate in the lawsuit. Those seeking lead plaintiff status or additional information about the litigation are required to contact the law firm within the specified timeframe.
The failed trial represents a critical setback for Vistagen's pipeline, as intranasal fasedienol was positioned as a potential treatment option for social anxiety disorder. Shareholders holding the company's securities during the relevant period and believing they suffered financial harm are encouraged to review their legal options and contact the firm for case details and eligibility requirements.